M Snajderová, J Lebl, D Zemková, S Kolousková, M Pechová
{"title":"[同时治疗生长激素和D-Trp-6-LHRH促性腺素类似物对中发性性早熟和生长激素缺乏症男孩生长预后的改善]。","authors":"M Snajderová, J Lebl, D Zemková, S Kolousková, M Pechová","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A boy with organically conditioned central precocious puberty and growth hormone deficiency (congenital cyst in the area of the third ventricle) is treated concurrently with an analog of gonadoliberine D-Trp-6-LHRH (Triptorelin) and growth hormone. Treatment was started at the calendar age od 9.4 years and bone age of 10.8 years. At the end of the first year of treatment the progression of bone age within one calendar year declined from 1.9 to 1.4 and after 18 months of treatment to 1.3. The growth rate increased from the initial value of 7.9 cm/year to 12.1 cm/year after 12 months of treatment, and subsequently reached a stable level of 10.2 cm/year. The growth prognosis increased markedly from the initial value of 168 cm to 174 cm at the end of the first year; a further improvement to 176 cm was recorded after 18 months of treatment.</p>","PeriodicalId":39741,"journal":{"name":"Cesko-Slovenska Pediatrie","volume":"49 1","pages":"25-8"},"PeriodicalIF":0.0000,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Improvement in the prognosis for growth in a boy with central precocious puberty and growth hormone deficiency treated concurrently with growth hormone and D-Trp-6-LHRH gonadoliberin analog].\",\"authors\":\"M Snajderová, J Lebl, D Zemková, S Kolousková, M Pechová\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A boy with organically conditioned central precocious puberty and growth hormone deficiency (congenital cyst in the area of the third ventricle) is treated concurrently with an analog of gonadoliberine D-Trp-6-LHRH (Triptorelin) and growth hormone. Treatment was started at the calendar age od 9.4 years and bone age of 10.8 years. At the end of the first year of treatment the progression of bone age within one calendar year declined from 1.9 to 1.4 and after 18 months of treatment to 1.3. The growth rate increased from the initial value of 7.9 cm/year to 12.1 cm/year after 12 months of treatment, and subsequently reached a stable level of 10.2 cm/year. The growth prognosis increased markedly from the initial value of 168 cm to 174 cm at the end of the first year; a further improvement to 176 cm was recorded after 18 months of treatment.</p>\",\"PeriodicalId\":39741,\"journal\":{\"name\":\"Cesko-Slovenska Pediatrie\",\"volume\":\"49 1\",\"pages\":\"25-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1994-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cesko-Slovenska Pediatrie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cesko-Slovenska Pediatrie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[Improvement in the prognosis for growth in a boy with central precocious puberty and growth hormone deficiency treated concurrently with growth hormone and D-Trp-6-LHRH gonadoliberin analog].
A boy with organically conditioned central precocious puberty and growth hormone deficiency (congenital cyst in the area of the third ventricle) is treated concurrently with an analog of gonadoliberine D-Trp-6-LHRH (Triptorelin) and growth hormone. Treatment was started at the calendar age od 9.4 years and bone age of 10.8 years. At the end of the first year of treatment the progression of bone age within one calendar year declined from 1.9 to 1.4 and after 18 months of treatment to 1.3. The growth rate increased from the initial value of 7.9 cm/year to 12.1 cm/year after 12 months of treatment, and subsequently reached a stable level of 10.2 cm/year. The growth prognosis increased markedly from the initial value of 168 cm to 174 cm at the end of the first year; a further improvement to 176 cm was recorded after 18 months of treatment.
期刊介绍:
So stúpajúcou prevalenciou exogénnej obezity v detskom veku je pozorovaný i čoraz častejší výskyt zmien v lipidovom a sacharidovom metabolizme. Ich mediátorom je inzulínová reziste...